MELANOTAN II

Skin, Hair & CosmeticResearch Only

Solid clinical evidence for both tanning and sexual effects, but documented cases of serious adverse events including kidney damage and potential cancer interactions make risk-benefit calculations complex.

Studied primarily by dermatology researchers investigating photoprotection and sexual medicine specialists exploring non-pharmaceutical erectile dysfunction treatments.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

30 total, 2 human

Popularity

#8 most researched

What is MELANOTAN II?

Originally developed as a potential sunless tanning agent, this synthetic peptide gained notoriety for its dual effects on skin pigmentation and sexual function. Research communities have examined it primarily for treating erectile dysfunction and seasonal affective disorder, though it's perhaps better known in cosmetic research circles for its melanin-stimulating properties.

The peptide binds to melanocortin receptors throughout the body, particularly MC1R in skin cells and MC4R in the brain and reproductive tissues. When it activates skin receptors, cells ramp up melanin production without UV exposure, creating a tan-like effect. Simultaneously, its action on brain receptors triggers cascades that enhance sexual arousal and libido through pathways normally involved in appetite and reward processing.

What the Research Shows

While 21 human studies provide substantial clinical data, the research is dominated by small-scale trials rather than large randomized controlled studies.

Clinical evidence for MELANOTAN II consists of 21 human studies including 3 randomized controlled trials. Key findings include efficacy for erectile dysfunction (85% response rate in affected men) and increased sexual desire, but also documented serious adverse events including renal infarction through thrombotic and toxic mechanisms and melanoma risk when combined with tanning bed use.